checkAd

     172  0 Kommentare Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation - Seite 4

    INVESTOR AND MEDIA CONTACTS 
    Innovation Pharmaceuticals Inc. 
    Leo Ehrlich 
    info@ipharminc.com


     

    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation - Seite 4 Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this monthWAKEFIELD, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) - Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased …